Get the Stockscreener App
103.99
0.55%
-0.58
After Hours:
103.80
-0.19
-0.18%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $103.99, with a volume of 10.91M.
It is down -0.55% in the last 24 hours and down -10.62% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$104.57
Open:
$104.9
24h Volume:
10.91M
Relative Volume:
1.03
Market Cap:
$180.70B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
27.98
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-1.39%
1M Performance:
-10.62%
6M Performance:
-22.13%
1Y Performance:
-20.83%
1-Day Range:
$103.68
$105.46
1-Week Range:
$102.41
$107.14
52-Week Range:
$102.41
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
103.99 | 180.70B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.44 | 125.40B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.17 | 102.80B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
79.34 | 45.74B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Net Worth Advisory Group Acquires Shares of 10,905 Abbott Laboratories $ABT - MarketBeat
Abbott subsidiary dodges whistleblower claim from fired remote worker - hcamag.com
Abbott Culture Alignment Supports Long Term Execution And Valuation Story - simplywall.st
Deal Dispatch: Estée Lauder Considers Merger, KKR Buys Nothing Bundt Cakes, Amazon Acquires Fauna Robotics - Benzinga
Abbott Laboratories Faces Weak Start with Gap Down Amid Market Concerns - marketsmojo.com
Abbott Labs Eludes Kentucky State-Law Claims in Heart Valve Suit - Bloomberg Law News
Abbott Laboratories $ABT Shares Acquired by Dakota Wealth Management - MarketBeat
Abbott Unit Beats Ex-Worker's Whistleblower Suit At 8th Circ. - Law360
Vanguard disaggregates holdings; ABT shows 0 shares (ABT) - Stock Titan
Abbott Labs Worker’s Wrongful Termination Suit Fails on Appeal - Bloomberg Law News
What Abbott Laboratories (ABT)'s Cancer Screening Deal and Libre Data Reveal About Its Chronic Care Ambitions - simplywall.st
Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences - Yahoo Finance
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
Abbott hosts conference call for first-quarter earnings - abbott.mediaroom.com
Abbott will report first-quarter results before markets open April 16 - Stock Titan
Abbott Laboratories stock faces pipeline scrutiny amid diagnostics slowdown in Q1 2026 - AD HOC NEWS
Abbott (NYSE: ABT) SVP receives 13,255-share restricted stock award - Stock Titan
[Form 3] ABBOTT LABORATORIES Initial Statement of Beneficial Ownership - Stock Titan
Mom Tying Abbott Formula To Baby's NEC Takes The Stand - Law360
Why Abbott (ABT) Is Betting $23B on Cancer Screening - MarketWise
Abbott Earnings Preview: What to Expect - Barchart.com
Abbott Laboratories Stock Hits Day Low of $105.40 Amid Price Pressure - Markets Mojo
Abbott Laboratories Hits New 52-Week Low at USD 104.11 - Markets Mojo
Abbott Laboratories stock faces pressure amid diagnostics slowdown and FreeStyle Libre competition i - ad-hoc-news.de
List of 29 Acquisitions by Abbott (Mar 2026) - Tracxn
Is It Time To Reconsider Abbott Laboratories (ABT) After Recent Share Price Weakness? - Yahoo Finance
Abbott Proclaim SCS Lawsuit Alleges Stimulator Lead Migration Resulted in Multiple Surgeries - AboutLawsuits.com
Abbott (ABT) Finalizes $21 Billion Exact Sciences (EXAS) Takeover - Blockonomi
Abbott (ABT) Stock Completes $21B Exact Sciences (EXAS) Acquisition - CoinCentral
Top Analyst Reports for Eli Lilly, RTX & Abbott - Yahoo Finance
Abbott Completes $21B Exact Sciences Deal To Expand Cancer Diagnostics - Citeline News & Insights
The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant - Yahoo Finance
Abbott (ABT) Stock Rated Buy on Strong Diabetes Trial Results - Insider Monkey
Abbott closes $23 billion deal to buy Madison-based Exact Sciences - Milwaukee Journal Sentinel
SG Americas Securities LLC Sells 102,478 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Labs completes acquisition of Madison’s Exact Sciences for $23 billion - Wisconsin State Journal
Nordea Investment Management AB Has $73.97 Million Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories raised prices, prompting sales slump - MSN
E. Ohman J or Asset Management AB Invests $7.72 Million in Abbott Laboratories $ABT - MarketBeat
Dynamic Advisor Solutions LLC Sells 15,282 Shares of Abbott Laboratories $ABT - MarketBeat
Avanza Fonder AB Boosts Stock Position in Abbott Laboratories $ABT - MarketBeat
Assenagon Asset Management S.A. Increases Position in Abbott Laboratories $ABT - MarketBeat
U.S. Medical Nutrition Market Is Going to Boom | Abbott Laboratories • Nestlé Health Science • Danone - openPR.com
Abbott Laboratories (ABT) Completes Acquisition of Exact Sciences - GuruFocus
Abbott Laboratories stock completes $21 billion Exact Sciences acquisition, eyes diagnostics growth - AD HOC NEWS
Abbott completes acquisition of Exact Sciences - Abbott MediaRoom
Abbott Completes Exact Sciences Acquisition to Transform Global Cancer Diagnostics - geneonline.com
Abbott Expands Healthcare Ecosystem With Exact Sciences Acquisition - Built In Chicago
Exact Sciences Corp stock delisted from Nasdaq after $21 billion Abbott acquisition completion - AD HOC NEWS
Abbott finalizes purchase of Madison-based Exact Sciences - Spectrum News
Abbott closes $21B Exact Sciences deal - Crain's Chicago Business
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):